30S Ribosomal Proteins for Safe Pluripotent Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing pluripotent cells, such as ES and iPS cells, face ethical concerns, immune rejection issues, and incomplete elimination of cancer risks, while standardization and safety in iPS cell technologies are still developing.
Innovation Solution
A composition comprising isolated and purified 30S ribosomal proteins (S2, S8, and S15) is used to reprogram human skin cells, forming cell clusters with pluripotency without gene introduction or forced expression, allowing for the production of cells with high safety for regenerative medicine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ES cells are used to produce pluripotent cells, then pluripotency is achieved, but ethical problems arise from using fertilized ova and immune rejection occurs when transplanted
Solution Approach 1:
The patent uses iPS cells as a copy alternative to ES cells. Instead of using fertilized ova (ES cells), the invention creates pluripotent cells by reprogramming somatic cells through infection with recombinant viruses containing specific transcription factors (Oct4, Sox2, Klf4, c-Myc), thereby obtaining ethically acceptable copies that avoid both ethical problems and immune rejection
Solution Approach 2:
The patent introduces recombinant viruses as intermediary carriers to deliver transcription factors into somatic cells. These viruses (e.g., retroviruses, lentiviruses) serve as mediators that enable reprogramming without direct manipulation of fertilized ova, thus resolving the ethical conflict while maintaining pluripotency
2Object-affected harmful factors
If iPS cells are used to avoid ethical problems and immune rejection, then safety is improved, but standardization is incomplete and cancer risks cannot be completely eliminated
Solution Approach 1:
The patent extracts and purifies specific ribosomal proteins (30S subunit proteins S2, S8, S15) from bacterial ribosomes and uses them as reprogramming factors. This extraction approach eliminates the need for complex viral vectors and gene insertion, thereby reducing cancer risks while maintaining the ability to generate standardized, safe iPS cells
Solution Approach 2:
The patent changes the reprogramming mechanism from genetic modification (virus-based) to protein-based reprogramming using purified ribosomal proteins. This parameter change from DNA-level manipulation to protein-level action reduces tumorigenicity and enables better standardization, directly addressing the reliability concerns while maintaining safety
3Reliability
If conventional reprogramming methods are used, then pluripotency is achieved, but the process complexity and difficulty of standardization increase
Solution Approach 1:
The patent employs disposable, easily obtainable bacterial ribosomal proteins as reprogramming factors instead of complex, hard-to-standardize viral vectors. These purified proteins can be produced through simple bacterial expression systems, dramatically simplifying the standardization process while maintaining effective pluripotency induction
Data Source
AI summary
An exemplary composition can be provided which includes an identified substance that induced cell reprogramming. Cells can also be provided having pluripotency having high safety when applied to regenerative medicine, using the composition, and a production method therefor. A cell reprogramming-inducing composition can include at least one 30S ribosome protein selected from the group consisting of 30S ribosome protein S2, 30S ribosome protein S8 and 30S ribosome protein S15 as a substance that reprograms cells derived from a mammalian animal is provided. Further, an exemplary production method for cells having pluripotency from somatic cells using the composition can be provided.